ライフサイエンス出版株式会社

FacebookTwitterInstagram
menu

Japan Society of Clinical Trials and Research ( JPT Supplement )

Vol. 49 Suppl. 1 2021

■ The 12th Annual Meeting "Change of Clinical Trials and Research —from First-in-Human to Big Data—"

SYMPOSIUM 1 Flexible Clinical Trial Design Based on Statistical Decision-making

1 Design of Small Clinical Trials

S. Teramukai

Jpn Pharmacol Ther 2021; 49(s1): s9-11.


2 Use of Basket Trial Design in Investigator Initiated Clinical Trials for Molecular-Targeted Agents

I. Yokota, et al

Jpn Pharmacol Ther 2021; 49(s1): s12-15.


SYMPOSIUM 2 Challenge of Digital Trials

1 Efforts of Investigator Initiated Trials for Amyotrophic Lateral Sclerosis (ALS) during the COVID-19 Pandemic

R. Oki, et al

Jpn Pharmacol Ther 2021; 49(s1): s16-18.


2 New Normal of Clinical Trial in Post COVID Era
  ──Focusing on the Experience of Virtual Clinical Trial, Home-Visiting Clinical Trial, and DCT

H. Nagashima

Jpn Pharmacol Ther 2021; 49(s1): s19-22.


3 Digital Shift of Clinical Trial Operation with Telemedicine and eSource as a New Standard of Post COVID-19

R. Kusama

Jpn Pharmacol Ther 2021; 49(s1): s23-25.


4 Consideration for Introduction and Adoption of Decentralized Clinical Trials in Japan

W. Takasawa

Jpn Pharmacol Ther 2021; 49(s1): s26-28.

■ ORIGINAL ARTICLES

Collaboration between Academia and Private Companies on Implementation of CDISC Standards:
A Survey of Pharmaceutical Companies and Contract Research Organizations(CRO)

T. Yamaguchi, et al

Jpn Pharmacol Ther 2021; 49(s1): s47-56.


Current Status and Promotion of Information Disclosure about Medical Institutions
for Patients Considering Participating in Clinical Trials

M. Yamaguchi, et al

Jpn Pharmacol Ther 2021; 49(s1): s57-62.

■ CASE REPORTS

Web Portal Development to Share Information about CDISC Standards in Academia

M. Yamamoto, et al

Jpn Pharmacol Ther 2021; 49(s1): s63-67.

■ BRIEF REPORTS

Examination of Consultation and Support for Nursing Research throughout
the Year at the Institute for Clinical and Translational Science

M. Uyama, et al

Jpn Pharmacol Ther 2021; 49(s1): s68-71.

■ TECHNOLOGY TRENDS

Bayesian Approaches in Rare Disease Drug Development

A. Hirakawa, et al

Jpn Pharmacol Ther 2021; 49(s1): s72-79.